Stocks Roche Holding AG

More

  • price to earnings calculations

    European equities closed sharply lower on Thursday, as a raft of weak earnings offset positive sentiment surrounding the rebound in oil prices.

  • The drug, alectinib, to be sold under the brand name Alecensa, was approved to treat patients with advanced ALK-positive non-small cell lung cancer whose disease has worsened after, or who could not tolerate, treatment with Pfizer's Xalkori. "Today's approval provides a new therapy for a group of patients who would have few treatment options once their disease...

  • NEW YORK, Dec 2- A U.S. appeals court refused on Wednesday to reconsider its decision invalidating a Sequenom Inc prenatal DNA test patent, a decision that could put in doubt the validity of a wide range of medical and biotechnology patents. Sequenom shares fell 9.5 percent to $1.62 on Wednesday. Sequenom's patent relates to the discovery of a way to detect fetal...

  • Goldman Sachs' 7 big predictions for the future Wednesday, 2 Dec 2015 | 2:20 PM ET
    An unmanned SpaceX Falcon 9 rocket launches from Cape Canaveral, Fla., June 28, 2015. The rocket exploded about two minutes after liftoff, destroying a cargo ship bound for the International Space Station, NASA said.

    Goldman's Robert Boroujerdi presented seven future theme predictions and their investment implications in a note to clients Wednesday.

  • Europe closes mixed; ECB in focus, Arcelormittal down 9% Wednesday, 2 Dec 2015 | 11:50 AM ET

    European equities closed the session mixed Wednesday as investors digested inflation numbers and contemplated the possibility of further stimulus.

  • Roche pulls out of "superbug" antibiotic project Sunday, 29 Nov 2015 | 11:00 AM ET

    VIENNA, Nov 29- Swiss drugmaker Roche Holding has dropped out of a high-profile project to develop an antibiotic for treating "superbug" infections, the company said on Sunday. Roche had agreed in 2013 to pay privately held partner Polyphor up to 500 million Swiss francs for rights to the product, marking a rare foray by a major pharmaceuticals company into the...

  • Nov 20- NovoCure Ltd said its lead cancer therapy improved survival rate in brain cancer patients in combination with Avastin in a late-stage study, sending its shares up 23 percent in extended trading. NovoCure's therapy, Optune, which was evaluated in combination with Roche Holding AG's cancer drug, reduced the risk of death by 39 percent in patients, compared...

  • The cancer therapy, Optune, which was evaluated in combination with Roche Holding AG's Avastin, reduced the risk of death by 39 percent in patients, compared with patients treated with Avastin alone, Novocure said in a statement on Friday.

  • Nov 20- New data from a midstage trial show that Celldex Therapeutics Inc's experimental brain cancer vaccine, combined with standard therapy, continues to improve chances of survival for patients with recurrent cancer. The updated results sent shares of Celldex up $1.74, or 12 percent, to $16.23 on the Nasdaq. David Reardon, clinical director at Dana-Farber...

  • Nov 20- New data from a midstage trial show that Celldex Therapeutics Inc's experimental brain cancer vaccine, combined with standard therapy, continues to improve chances of survival for patients with recurrent cancer. The vaccine, designed to enlist the body's immune system to fight glioblastoma multiforme, showed that 25 percent of patients given...

  • Norway's giant oil fund sees biggest loss in 4 years Wednesday, 28 Oct 2015 | 8:56 AM ET
    A visitor looks out towards a flare stack on the Oseberg A offshore gas platform operated by Statoil ASA in the North Sea 140kms from Bergen, Norway.

    Norway's sovereign wealth fund, the largest in the world by assets, reported a loss in the third quarter of this year as the global sell-off in risk assets hit the fund's equity holdings.

  • Europe ends up 2% on ECB hints; euro slips, earnings eyed Thursday, 22 Oct 2015 | 11:30 AM ET
    European Central Bank President Mario Draghi

    European markets jumped higher on Thursday, after the European Central Bank's president said that policy would be re-examined in December.

  • Oct 22- ImmunoGen Inc said the gastric cancer drug it is developing with Roche Holding AG did not meet the main goal in a large study. ImmunoGen entered into a royalty purchase agreement with Roche for Kadcyla this year. The drug raked in revenue of about $580.3 million this year.

  • Gastric cancer drug from ImmunoGen, Roche fails study Thursday, 22 Oct 2015 | 7:26 AM ET

    Oct 22- ImmunoGen Inc said the gastric cancer drug it is developing with Roche Holding AG did not meet the main goal in a large study. ImmunoGen entered into a royalty purchase agreement with Roche for Kadcyla this year. Kadcyla is already approved for the treatment of late-stage breast cancer and was being tested as a second-line treatment for gastric cancer in...

  • At least half a dozen drugs, including colon cancer treatments Cyramza, from Eli Lilly& Co, and Stivarga, sold by Bayer AG, aren't worth prices that can exceed $100,000 a year, top cancer specialists said in interviews with Reuters. If specialists do start considering a drug's cost in their prescribing habits, such decisions could dent the multibillion-dollar...

  • Sept 24- GlaxoSmithKline Plc said the European health regulator had recommended an approval for its injectable drug to treat asthma patients who don't respond well to traditional inhalers. GSK and other drugmakers including AstraZeneca Plc, Roche Holding AG, Teva Pharmaceutical Industries Ltd and Sanofi SA are developing drugs that take a more...

  • Sept 22- A company formed by genome pioneer Craig Venter will offer clients of a South Africa- based insurance company whole exome sequencing- sequencing all protein-making genes in the human genome- at a price that marks yet another dramatic decline in the cost of gene sequencing, the two companies said on Tuesday. Venter's company, Human Longevity Inc, will...

  • Buy or sell Germany? Friday, 7 Aug 2015 | 2:05 PM ET
    The Brandenburg Gate in Berlin, Germany

    DAX all folks

  • Europe closes lower; earnings dominate Thursday, 23 Jul 2015 | 11:30 AM ET

    European stocks ended lower on Thursday, after a flurry of corporate earnings came out from across the region.

  • Roche CEO warns on high pharma valuations Thursday, 23 Jul 2015 | 6:26 AM ET

    Valuation are "very high" in the pharmaceutical sector, Roche CEO Severin Schwan told CNBC on Thursday after the company posted a rise in sales.